All In Biotech

Investigational drug · Phase 3

Rocbrutinib

Also called: LP-168, NWP-775

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

6 still active

All registered trials

9

Any phase or sponsor naming "Rocbrutinib"

First trial start

2023

Feb 21, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Rocbrutinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Mantle Cell Lymphoma (MCL)
  • Mantle Cell Lymphoma
  • Relapsing-remitting Multiple Sclerosis (RRMS)
  • Follicular Lymphoma ( FL)
  • Waldenström Macroglobulinemia (WM)
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
  • CLL / SLL
  • CLL (Chronic Lymphocytic Leukemia)
  • CLL, Refractory

Approved drugs for the same conditions: Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Multiple sclerosis · Hematology and blood cancers · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "Rocbrutinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Diffuse Large B-Cell Lymphoma (DLBCL)

  • BirelentinibDZD8586Phase 37 trials

    Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)

  • OdronextamabREGN1979, OrdsponoPhase 37 trials

    Regeneron · Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed/Refractory Follicular Lymphoma

  • AbexinostatPCI-24781Phase 35 trials

    Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma

  • CyclophosphamidPhase 33 trials

    Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer

  • CRC01Phase 22 trials

    Curocell Inc. · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)

  • LacutoclaxPhase 22 trials

    Guangzhou Lupeng Pharmaceutical Company LTD. · Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)

  • TRS005Phase 22 trials

    Zhejiang Teruisi Pharmaceutical Inc. · CD20-positive Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL)

  • REGN9220Phase 21 trial

    Regeneron · Diffuse Large B-Cell Lymphoma (DLBCL)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.